Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. reports successful completion of early-stage clinical trials for their proprietary microdosing treatment, MB22001, showing significant potential to alleviate depressive symptoms. The company has launched Phase 2B trials, including groundbreaking home-use studies, positioning itself as a leader in psychedelic medicine on the Canadian Securities Exchange.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
